Femasys Inc. Announces Enrollment Completion for Stage 2 Study of FemBloc for Permanent Birth ControlGlobeNewsWire • 10/06/22
Femasys Inc. Announces the Commercial Availability of FemCerv® for Cervical Cancer Screening and Expands Management TeamGlobeNewsWire • 09/29/22
Femasys Inc. to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewsWire • 09/01/22
Femasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2022 and Provides Corporate UpdateGlobeNewsWire • 08/10/22
Femasys to Participate in the Women's Health Panel Discussion Presented by Maxim Group LLC and hosted by M-Vest on Wednesday, July 13th at 11 a.m. ETGlobeNewsWire • 07/11/22
Femasys Inc. Announces Financial Results for the First Quarter Ended March 31, 2022GlobeNewsWire • 05/11/22
Femasys Inc. Announces Financial Results for the Year Ended December 31, 2021GlobeNewsWire • 03/24/22
Femasys Inc. Announces the Appointment of Edward Evantash, M.D. as Chief Medical OfficerGlobeNewsWire • 09/01/21